Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
about
Possible interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor complex.Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysisModification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits.Assessment of the effects of combination therapy with ciprofloxacin and fenbufen on the central nervous systems of healthy volunteers by quantitative electroencephalography.Oral absorption of ofloxacin administered together with aluminum.Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs.Pharmacokinetics of rufloxacin in patients with impaired renal function.Lomefloxacin pharmacokinetics in subjects with normal and impaired renal functionMultiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteersPharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days.Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects.Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patientsEffects of ciprofloxacin on testosterone and cortisol concentrations in healthy males.Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data.Effects of two cations on gastrointestinal absorption of ofloxacin.Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers.Gingival fluid ciprofloxacin levels at healthy and inflamed human periodontal sites.Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.The effects of food on drug bioavailability.Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin.In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteersPharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro.Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review.Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule.Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study.Absence of pharmacokinetic interference of moxifloxacin on cyclosporine and tacrolimus in kidney transplant recipients.Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid.
P2860
Q24538958-837D0D50-491C-45F9-B1A2-9EA13BBD3FC0Q28360207-FAF22EAA-F137-48F5-B009-7B612460BFC5Q33593726-C7953DF7-4406-4921-B68B-D8580C9E8E6AQ33696090-65500E9D-4366-49A9-96E0-B6B67ACB6F85Q33762484-7CE10BC3-6F8D-4A12-BF00-FA5351170932Q33843878-F85FBCEC-18CC-4D9B-B3C0-52F7757F7C88Q34729777-84D2C21C-5E9C-4266-845F-788CE3B98266Q35245293-A3A9E715-0CD7-4B7D-BE93-86E7B2D441F5Q35245897-67C33387-1B4C-492C-AA06-CC4F85ED9309Q35246804-EF81BA86-46A4-4F1A-A1CC-6573371D071AQ35253425-D1889817-B049-43F4-8F73-BFC06DE9A241Q35285443-DEE58F9D-61C8-498C-ACAD-B69E494C54CFQ35358691-35DDE924-F702-499D-A7B0-79C00D44F230Q36718935-83F6B3C3-859F-4D6F-83FA-7BF5F42E5280Q36755927-A02AB72B-EB70-40F6-8FA7-0E539623A107Q36757133-64D2AF09-F32E-44C6-8DAE-6B9ECF91AB25Q36789986-F028DAFC-6B1C-4BB7-85D3-5C19AF3EA16FQ36863646-C00ECD5D-A5CE-452F-A133-A1E0D9A6750CQ38755040-2CE86428-C29C-451F-AD7C-B51C88D34022Q39470224-D70CC667-4121-4FF2-89BE-B7E3D02C2891Q39815676-5485EA1C-76DC-47A2-B9BA-BD71EC8BCE4EQ39816080-9128E703-4303-45DB-8B5B-16F04153E13AQ39816969-E0CA575F-135D-4EB6-A6F6-16F78E910DB2Q39869167-6DD3EF1A-2531-4AA0-889B-251667D937A9Q41698366-6E2B6276-C008-41B9-8918-0E27AE91CB0FQ42285019-E73B62B9-CC11-4E51-A908-82DB9B43DA2AQ43103062-58F60D6B-AD1B-4783-B06E-C658276C06D2Q43188224-B8B4326E-174A-4266-AD29-2E7A3D46A315Q43441129-672CE531-4D13-412D-95B5-F477F828A2AB
P2860
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
@en
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
@nl
type
label
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
@en
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
@nl
prefLabel
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
@en
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
@nl
P1476
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
@en
P2093
P304
P356
10.2165/00003088-198814020-00003
P577
1988-02-01T00:00:00Z
P6179
1000873912